AKSHIT CHITKARA

Dr. AKSHIT CHITKARA

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2023 in Cancer Medicine
Verified
Journal Article
Open access
ACAKSHIT CHITKARA
AKSHIT CHITKARA
NKNirmaljot Kaur
Nirmaljot Kaur
ADAditya Desai
Aditya Desai
DMDevanshi Mehta
Devanshi Mehta
FAFnu Anamika
Fnu Anamika
ECEmerson Y. Chen
Emerson Y. Chen
Background: Guidelines show that for metastatic colorectal cancer (mCRC), a combination of three‐drug regimens, fluorouracil, leucovorin, and oxaliplatin and bevacizumab (BVZ), is one of the first‐line standard therapies. BVZ is generally well tolerated; however, it is associated with infrequent, life‐threatening side effects such as severe hypertension (HTN) (5%–18%), Grade ≥3 arterial thromboembolism (ATE) (2.6%), Grade ≥3 hemorrhagic events (1.2%–4.6%), and gastrointestinal perforation (0.3%–2.4%). This meta‐analysis aims to evaluate the additive risk of BVZ‐induced severe HTN and thromboembolism when BVZ is combined with a standard chemotherapy regime in patients with mCRC.Methods: Our search was conducted from January 29, 2022, to February 22, 2022, through databases of PubMed, clinicaltrial.gov, EMBASE, Web of Science, and Cochrane Library. Data analysis from randomized controlled trials (RCTs) and clinical trials was conducted using Review Manager V.5.4, comparing BVZ‐chemotherapy to chemotherapy only, focusing on cardiovascular AE such as HTN and arterial and venous thromboembolism.Results: The analysis from 26 clinical trials and RCTs showed that the odds of HTN were about four times higher, and ATE subgroup analysis of 11 studies showed over two times higher odds of ATE in patients being treated with BVZ compared to the chemotherapy‐only group.Conclusion: BVZ, when added to the standard chemotherapy regimen for mCRC, was associated with higher odds of developing HTN and thromboembolism, specifically ATE, than the chemotherapy‐only group. Our findings are significant as they provide vital information in analyzing the risk–benefit ratio of adding BVZ to the standard chemotherapy regime in patients with mCRC, especially in patients with vascular comorbidities.

7 September 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
ACAKSHIT CHITKARA
AKSHIT CHITKARA
MBMuhammad Bakhtiar
Muhammad Bakhtiar
ISIbrahim Sahin
Ibrahim Sahin
DHDennis Hsu
Dennis Hsu
JZJanie Zhang
Janie Zhang
ASAnwaar Saeed
Anwaar Saeed
Recent trials provide evidence that HER2 is a potential new target for patients with colorectal cancer. While HER2-positive tumors do not show a very encouraging response to anti-HER2-positive agents like trastuzumab alone, promising results have been observed when combined with other synergistically acting tyrosine kinase inhibitors (TKIs). Our meta-analysis was conducted following the Cochrane Handbook and written following the PRISMA guidelines. The protocol was registered on PROSPERO with the registration number CRD42022338935. After a comprehensive search for relevant articles, 14 CTs were identified and uploaded to Rayyan, and six trials were ultimately selected for inclusion. The meta-analysis revealed that a median of three prior lines of therapy was used before enrolling in the six trials comprising 238 patients with HER2-positive metastatic colorectal cancer (mCRC). The pooled objective response rate (ORR) and disease control rate (DCR) were 31.33% (95% confidence interval [CI] 24.27–38.39) and 74.37% (95% CI 64.57–84.17), respectively. The pooled weighted progression-free survival (PFS) was 6.2 months. The pooled ORR and DCR meta-analysis indicate a significant response to HER2-targeted therapy in this patient in HER2-positive mCRC. Additionally, a pooled PFS of 6.2 months suggests that HER2-targeted treatment regimens are associated with a meaningful improvement in survival outcomes in this population.

30 July 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
ACAKSHIT CHITKARA
AKSHIT CHITKARA
SSSushanth Sreenivasan
Sushanth Sreenivasan
YYYue Yin
Yue Yin
MRMaitreyee Rai
Maitreyee Rai
SSSanthosh Sadashiv
Santhosh Sadashiv
Chimeric Antigen Receptor T-cell (CAR-T) therapy uses genetically engineered T-cells with specific binding sites. This therapy allows for tumor specificity and durable treatment responses for patients with hematological malignancies. In this review, we study the risk of venous thromboembolism (VTE) associated with CAR-T therapy. We searched the National Institutes of Health library, Cochrane Library Databases, ClinicalTrials.gov database, and medical literature search engines PubMed and Google Scholar for Phase 2 and Phase 3 drug-efficacy and safety trials to determine the aggregate incidence and risk of VTE treated with CAR-T. Of 1127 search results, nine studies were identified and included in our meta-analysis. Of the 1017 patients who received therapy, 805 patients (79.15%) experienced some degree of CRS, and 122 patients (11.9%) experienced severe CRS (higher than grade 3). Only three out of one thousand and seventeen patients were reported to have experienced venous thromboembolism. Our study did not find a statistically significant association between increased VTE incidence (OR = 0.0005, 95% CI [0.0001, 0.0017]) and CRS/ICANS (p < 0.0001). There was a 0.0050 (95% confidence interval [0.0019, 0.0132]) relative risk for VTE. In our study, we did not find a statistically significantly increased risk of developing VTE despite CRS and underlying malignancy, which have been associated with increased risk of VTE.

11 October 2024 in Annals of Oncology
Verified
Journal Article
Closed access
EHE. Harris
E. Harris
NTN.F. Taflin
N.F. Taflin
ACAKSHIT CHITKARA
AKSHIT CHITKARA
MTMarco Tagliamento
Marco Tagliamento
CBC.M. Bestvina
C.M. Bestvina
Rajat ThawaniRajat Thawani
Rajat Thawani

9 June 2023 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
PCPrithi Choday
Prithi Choday
ACAKSHIT CHITKARA
AKSHIT CHITKARA
CBCarlos Buitrago
Carlos Buitrago
GSGeorge Saffouri
George Saffouri
AKAnas Kawayeh
Anas Kawayeh